ID Week

University of Washington’s Peter Rabinowitz, M.D., M.P.H., sees a world awash in emerging diseases and climate change data but says it needs to be delivered to clinicians in a form that they can use at the point of care, possibly via the electronic medical record.

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter Rabinowitz, M.D., M.P.H.

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted results of two real-world evidence studies of Apretude as an HIV prevention medication.

IJ Anosike, M.D., M.P.H., assistant professor of pediatrics at the Montefiore Medical Center in the Bronx, explains how COVID fatigue can lead to a downward trend in children getting the proper vaccines.

The CDC’s Timothy M. Uyeki, M.D., cautioned, however, that if the virus changes, and especially if it begins to infect pigs, that would be a game changer, allowing the virus to mutate to one that is more of a threat to people.

Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.

Patients with HIV who receive Cabenuva injections are more closely followed by physicians to assess the risk of cardiovascular, liver and kidney disease.

Even people living with HIV who have undetectable viral loads experience elevated inflammation levels, explained Michelle Cespedes, M.D., M.S, of Mount Sinai Health System.

Building relationships with state and local officials and repairing the tattered primary care system in the U.S. were some of the suggestions made at the opening plenary session of ID Week 2024.

Recent outbreaks of infections related to procedures done outside the United States, such as the fungal meningitis outbreak last year related to cosmetic surgery in Mexico, demonstrate the risks of medical tourism.

The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on injection long-acting PrEP.

The Centers for Disease Control and Prevention provides funding for HIV prevention for the populations at the highest risk of infection. State efforts to shift priorities could lead to poorer outcomes, more deaths and increased costs.

Identifying the priority populations for PrEP is crucial for guiding the future HIV prevention options, researchers said.

Interim results of a phase 2 trial indicate that the mpox vaccine MVA-VN has an immune response in adolescents similar to that of adults with no safety signals six months after the last dose.

Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.

Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says that as the most common infectious cause of long-term disability CMV should be the number one target of vaccine development.

If you want a strong workforce, you need to build it to be diverse and inclusive, said members of a panel on diversity and inclusion.

Climate change and global travel have brought a reemergence in the United States of viral diseases spread by mosquitos.

Su Wang, M.D., M. P.H., of Cooperman Barnabas Medical Center says liberalizing and simplifying hepatitis B treatment guidelines would elevate patient-centered decision-making and help reduce transmission of the virus.

Two-thirds of patients with renal comorbidities achieved “clinical success” with the new fecal microbiota treatment for C. difficile.

Patients with chronic kidney disease and other renal impairments tend to have worse outcomes from C. difficile infections.

The CDC has learned from the COVID-19 pandemic and is making changes to better identify and respond more effectiively to threats to public health.

At this year’s ID Week conference in Boston, Igho Ofotokun, MD, MSc, FIDSA, Grady Distinguished Professor of Medicine at the Emory University School of Medicine, shared the latest data that COVID-19 research team, RECOVER, has gathered on Long COVID and its symptoms.

Research has found that for patients with recurrent C. diff infections, improving the microbiome is helpful to patients’ physical, mental and social status.

The chair of Harvard Medical School’s bioinformatics department says the deterministic, discrete data of billing and reimbursement means that artificial intelligence’s first big impact in healthcare is likely to be in “the business of healthcare.”

Research of broadly neutralizing antibodies — which are able to neutralize multiple strains of HIV — have the potential to treat, prevent and maybe even cure HIV.